UNSPSC 51121617: Ranolazine

This classification denotes an enzyme inhibitor and cardiotonic agent with the molecular formula C24H33N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A6IEZ5M406, chemically known as 1-piperazineacetamide, n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)- but generally known as ranolazine, which bears US NIH Compound Identifier 56959. European Medicines Agency schedules Ranolazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10259MIG.

UNSPSC 51121617 Ranolazine, a Commodity code, encompasses pharmaceutical supply contracts that state and local governments solicit for emergency medical services, health plan formularies, and institutional pharmacy programs. State and local buying under this code centers on individual medication line items procured through sealed bids, cooperative purchasing agreements, and market-information-gathering RFIs. Issuing bodies include municipal fire rescue departments (Tampa Fire Rescue via the City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance/MMCAP). The geographic spread includes Florida, Texas, Minnesota, and Oregon, with MMCAP serving multiple participating jurisdictions across state lines.

Representative recent opportunities include Tampa Fire Rescue's sealed-bid IFB (No. 26P00188, due April 8, 2026) seeking four Advanced Life Support Medications line items—Labetalol HCI, Epinephrine, Adenosine, and Diltiazem—with an estimated contract value of $40,000.00 and a Small Local Business Enterprise sheltered-market 5 percent bid discount; the Minnesota Department of Administration's MMCAP RFP (No. S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with contract start July 1, 2026 and a 3 percent administrative fee; and the Texas HHS Commission's RFI (No. HHS0017013, due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs as a precursor to formal competitive procurement. Procurement patterns reflect both routine supply buys with firm expiration-date and delivery requirements, and longer-term strategic initiatives to improve pharmacy benefit management efficiency through consolidated contracting.